Treating women for preterm labor does not remove risk

05/13/2008 | Medscape (free registration)

Pregnant women who get prophylactic tocolytic therapy with 17-alpha-hydroxyprogesterone caproate because of a history of preterm delivery remain at high risk, researchers say. The study of 1,117 such women shows 44% developed preterm labor, with 23% going into labor at less than 34 weeks. Some 73% of women who developed preterm labor had recurrent episodes.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC
Associate Director, Compliance & Ethics, US Operations Ops II
Bristol-Myers Squibb
Plainsboro, NJ
Senior Associate, Health Economics - Heart Valve Therapy
Edwards Lifesciences
Irvine, CA